Stock in Action: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
BioMarin Pharmaceutical Inc. stock identified change of 33.60% away from 52-week low price and recently located move of -16.10% off 52-week high price. It has market worth of $15397.35M. BMRN stock has been recorded 0.44% away from 50 day moving average and 5.82% away from 200 day moving average. Moving closer, we can see that shares have been trading -3.12% off 20-day moving average.
BioMarin Pharmaceutical Inc. (BMRN) recently reported the transition of Executive Vice President and Chief Financial Officer Dan Spiegelman. Mr. Spiegelman will remain as an employee and senior advisor until September 1, 2020 to assist with the transition. After that, he plans to pursue other interests and spend more time with family. Brian R. Mueller, Senior Vice President, Finance and Chief Accounting Officer, has assumed the role of acting Chief Financial Officer. The Company is initiating an internal and external search for the role of Chief Financial Officer.
“On behalf of the entire Board and executive team, I would like to thank Dan for his important contributions and leadership during his tenure at the company. Over the last seven and a half years, he has played an invaluable role in supporting the company’s growth,” stated Jean-Jaques Bienaimé, Chairman and Chief Executive Officer. “I am confident that Brian in the acting CFO role will help us build on the strong foundation established and seamlessly execute on our business strategies. A veteran at BioMarin with 17 years of experience at the company, Brian has a deep knowledge of our business and throughout his career here has been essential in laying the ground work for BioMarin’s continued long-term success.”
Mr. Mueller has been with BioMarin since December 2002, during which time he has taken on roles of increasing responsibility. He has served as the Chief Accounting Officer since March 2011. Previous to that, Mr. Mueller served as Group Vice President, Corporate Controller. Mr. Mueller is a member of the board of directors and the Chairman of the Audit Committee of Anthera Pharmaceuticals, Inc. Before joining BioMarin, Mr. Mueller worked for KPMG as a senior manager in the firm’s audit practice. Before, he spent seven years with Arthur Andersen LLP in the firm’s audit and business advisory services practice.
The Healthcare sector company, BioMarin Pharmaceutical Inc. noticed change of 0.61% to $84.01 along volume of 755376 shares in recent session compared to an average volume of 1404.13K. BMRN’s shares are at 14.75% for the quarter and driving a -14.81% return over the course of the past year and is now at -0.64% since this point in 2018. The average volatility for the week at 2.38% and for month was at 2.54%.